ArticleCureus2025
Middle Meningeal Artery Embolization as a First-Line Therapy for Chronic Subdural Hematoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic subdural hematoma (cSDH) is a common neurovascular condition, particularly among elderly or anticoagulated patients. Its recurrence after surgical evacuation remains a major challenge. Middle meningeal artery embolization (MMAE) has recently emerged as a minimally invasive and durable alternative treatment, targeting the vascular networks that sustain hematoma membranes. We describe a patient with metastatic prostate cancer who developed a spontaneous cSDH and underwent first-line MMAE due to high surgical risk. Angiography revealed multifocal patchy dural enhancement resembling tumor blush, which was later confirmed on MRI to represent leptomeningeal metastasis. To our knowledge, the middle meningeal angiographic appearance of leptomeningeal disease seen in this case is previously unpublished. Embolization using 100-300 μm embospheres and coils achieved complete occlusion of the vessel and clinical improvement without recurrence. This case highlights the growing role of MMAE as a safe, effective first-line therapy for cSDH, supported by recent clinical trials demonstrating significant reductions in recurrence compared with conventional management. This report also underscores the importance of correlating angiographic findings with MRI when unique neoplastic vascular patterns are suspected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.